Oncopeptides AB (STO:ONCO), a pharmaceutical company developing drugs for the treatment of cancer, announced on Wednesday that data from its phase 1/2 O-12-M1 study evaluating melflufen, a lipophilic peptide-conjugated alkylator belonging to the novel class of peptidase enhanced cytotoxics, in the treatment of relapsed/refractory multiple myeloma (RRMM), have been selected for poster presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place between 31 May 2019 to 4 June 2019 in Chicago.

Reportedly, this data offers an analysis of time to next treatment (TTNT) in patients with RRMM who were treated with melflufen and dexamethasone in the phase 1/2 clinical study named O-12-M1. TTNT is used in Real World Evidence to assist treatment decisions and support economic reimbursement modelling.

According to the company, the early-stage clinical data being presented offer insights into the potential clinical application and utilisation of melflufen, which is also being studied now in the global, phase 3 OCEAN trial.